Our healthcare and business law firm works with many providers who work with compounded medications. Our firm previously posted Two Considerations When Prescribing Compounded Weight Loss Drugs on July 14, 2025, which gives an overview of several considerations that providers should consider before prescribing compounded weight loss drugs as part of their practice. We have recently encountered other issues related to compounded weight loss drugs, including prescribers offering compounded glucagon-like peptide-1 (“GLP-1”) drugs with ingredients such as retatrutide and cagrilintide, that have created separate legal risks regarding compounded weight loss drugs. If you are interested in prescribing compounded weight loss drugs as part of your practice or would like to discuss this blog post, you may contact our healthcare and business law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.
Background
Retatrutide is a GLP-1 peptide that has shown promise in clinical trials as a weight loss drug, but the Food and Drug Administration (“FDA”) has not approved retatrutide for any nonexperimental use in humans. Cagrilintide is different from a GLP-1 drug and has also shown promise as a weight loss drug along with semaglutide, the active ingredient in popular weight loss drugs like Ozempic® and Wegovy®, and Novo Nordisk, the maker of Ozempic®, has a clinical trial to determine if cagrilintide can be an effective weight loss drug standing alone.
First Consideration: The FDA Prohibits Providers from Compounding Retatrutide and Cagrilintide
The FDA has recently issued guidance expressing the agency’s concerns about providers prescribing unapproved GLP-1 drugs for weight loss. In this guidance, the FDA explicitly stated that retatrutide and cagrilintide cannot be used in Continue reading ›
























